BPC-157 (also known as BPC-157) is a therapeutically researched peptide studied for its effects on healing, recovery, tissue repair. Synthetic peptide from gastric juice promoting tissue repair, gut healing, and anti-inflammatory effects. Strong animal evidence, limited human trials. Not FDA-approved.
BPC-157 (Body Protection Compound-157) is a synthetic 15-amino acid pentadecapeptide derived from a protective protein found in human gastric juice. It works by promoting angiogenesis (new blood vessel formation), enhancing growth hormone receptor expression, and reducing inflammatory cytokines. Primarily researched for accelerating tissue repair, wound healing, gut health, and musculoskeletal injury recovery.
Overview
BPC-157 has shown robust regenerative and cytoprotective effects in preclinical animal studies, particularly for tendon, ligament, muscle injuries, and gastrointestinal disorders.
However, human clinical evidence remains extremely limited with only three small pilot studies conducted to date.
It is not FDA-approved for therapeutic use and is classified as a prohibited substance by the World Anti-Doping Agency (WADA).
While generally well-tolerated in animal studies, quality control concerns exist as it remains an unregulated compound.
BPC-157 is considered investigational and requires more comprehensive human clinical trials to establish safety, efficacy, and proper clinical applications.
Mechanism of action
Speeds healing of tendons, ligaments, muscles, and gut. Reduces inflammation and muscle soreness. Minimizes scar tissue formation.
Reported effects
Effects reported in the literature and from preclinical models include:
- Accelerates tendon fibroblast outgrowth, enhances cell survival under oxidative stress, and increases dose-dependent migration via FAK-paxillin pathway activation in rat Achilles tendon ex vivo and in vitro models [2] Preclinical
- Produces concentration-dependent, endothelium-dependent vasorelaxation in isolated human internal mammary artery rings via the nitric oxide synthase pathway [5] Preclinical
- Promotes angiogenesis and fibroblast activity by activating VEGFR2 via the Akt-eNOS axis and ERK1/2 signaling, with particular efficacy in poorly vascularized tissues such as tendons and myotendinous junctions [1] Preclinical
- Intravenous infusion of 10–20 mg in 2 healthy adults produced no measurable adverse effects on cardiac, hepatic, renal, thyroid, or glucose biomarkers in an IRB-approved pilot study [3] Phase I
- Demonstrates regenerative and cytoprotective effects across numerous animal models positioning it as a candidate for musculoskeletal medicine, though human evidence remains limited to three small pilot studies with no reported adverse effects [1][4] Preclinical
Evidence grades: FDA approved Phase III Phase II Phase I Preclinical Anecdotal
Dosage and administration
Subcutaneous
- Beginner: 200-250mcg daily, split into 2 doses (100-125mcg each, 12 hours apart)
- Intermediate: 300-400mcg daily, split into 2 doses (150-200mcg each, 12 hours apart)
- Acute injury: 400-500mcg daily for 2-4 weeks, then reduce to maintenance
Oral
- General: 500-1000mcg daily (lower bioavailability, better for gut issues)
Cycle
- 4-8 weeks on, 2-4 weeks off
Weight
- based: 2.5-3.75mcg per kg body weight, taken twice daily
Natty status
BPC-157 is generally regarded as compatible with the natty designation, particularly when used for therapeutic healing purposes. Opinions vary across natural bodybuilding federations, and athletes who compete should consult the rulebook of their respective sanctioning body.[6]
Research
The peptide has been the subject of 11 studies and reference works collected on this site. The full bibliography is in § External links below.
Related compounds
Other peptides in this catalogue with overlapping mechanisms or status:
References
- a b Narrative review on regeneration or risk
- ^ Tendon healing study
- ^ Safety evaluation
- ^ Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance.
- ^ Endothelium-Dependent Nitric Oxide-Mediated Vasorelaxant Effects of BPC 157 in Human Internal Mammary Artery.
- a b World Anti-Doping Agency. (2026). Prohibited List 2026.
External links
- Wikipedia article
- Systematic review of musculoskeletal healing
- Gastric cytoprotection study
- Wound healing mechanisms research
- Therapeutic peptides in gerontology: mechanisms and applications for healthy aging.
- Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives.
- 10mg BPC-157 — commercial
- Bacteriostatic Water Reconstitution Solution 10ml — commercial
This page was last edited on May 25, 2026, at 01:13 (UTC).
Text is available under the Creative Commons Attribution-ShareAlike License; additional terms may apply.